Contact DataPhone: + 34 935 801 853
Fax: + 34 935 805 729
Nanomol group's website
Primiano Pio Di Mauro was born on 24th of April 1983 in Italy. In 2002, he obtained his scientific high school qualification with honors and started to attend the courses of Biomedical Engineering at Politecnico di Milano (Milan, Italy), leading to his Bachelor of Science Degree. In 2009, he obtained a Master of Science degree in Biomedical Engineering at Politecnico di Milano, with a specialization in Biomaterials. In May 2010, he joined the Materials Engineering Group at IQS (Institut Quimic de Sarria) at the University of Ramon Llull in Barcelona (Catalunya, Spain) and in 2014 received his PhD with Special mention Doctorate Cum Laude. During his PhD thesis he worked at IQS and at CIC-biomaGUNE (San Sebastian, Basque Country, Spain) under the supervision of Prof. Dr. Salvador Borrós (Academic Professor and Head of Material Science Department) and Jordi Llop, PhD (Head of Radiochemistry Department). During his PhD, he worked as a researcher at Sagetis Biotech, a drug delivery company focused on designing of versatile and polymeric-based platforms for drug delivery through difficult-to-cross barriers (e.g blood-brain barrier, intestinal mucus gel layer). Currently, he works in NANOMOL Group at Materials Science Institute of Barcelona (ICMAB-CSIC) as a post-doctoral researcher under the supervision of Dra. Nora Ventosa and Jaume Veciana. He is working on design and physical-chemical and biological characterization of nanostructured systems and nanovehicles (polymeric and vesicular) for the encapsulation of active pharmaceutical ingredient.
Dr. Primiano Pio Di Mauro is interested in design and synthesis of versatile and polymeric or lipid-based platforms for drug delivery through difficult-to-cross barriers (e.g blood-brain barrier, intestinal mucus gel layer). Also he works on the development of nanomedicines or nanoconjugates with better properties of internalization, bioavailability and therapeutic efficacy for pulmonary, ocular, dermal and other pathways administration. For this aim, his work ranges from (i) synthesizing novel biodegradable polymers to be employed for developing polymeric drug delivery system with the aim of treating tumors to (ii) designing of engineered and versatile targeted nano-systems and nanovehicles (polymeric and vesicular) for the encapsulation and delivery of active pharmaceutical.
2007 Bachelor of Science (B.Sc.), Biomedical Engineering. Politecnico di Milano
2009 Master of Science (M.Sc.), Biomedical Engineering. Politecnico di Milano
Doctorate, University and Year:
2014 Doctor of Philosophy, Bioengineering. IQS, Institut Químic de Sarrià, Universitat Ramon Llull. Barcelona, Spain
- Polymeric Materials Synthesis
- Nanoparticles Synthesis and Characterization
- Polymeric Nanoparticles
- Lipid Nanoparticles
- Cancer Nanotechnology
- Targeted Drug Delivey
- Radioactive labeling
Most significative academic merits
Special mention Doctorate Cum Laude, IQS, Institut Químic de Sarrià, Universitat Ramon Llull.
IndicatorsNumber Articles: 4 Number Patents: 1
POLYMERIC NANOPARTICLES FOR DRUG DELIVERY
Patent US20140213641A1 31th July 2014 Also published as: EP2706989A1,WO2012153286A1 Inventors: Primiano Pio Di Mauro, Salvador Borrós
Novel 18F labeling strategy for polyester-based NPs for in vivo PET-CT imaging.
Primiano Pio Di Mauro, Vanessa Gómez-Vallejo, Zurine Baz, Jordi Llop, Salvador Borros. Bioconjugate Chemistry 02/2015; 26(3).
Development of High Drug Loaded and Customizing Novel Nanoparticles for Modulated and Controlled Release of Paclitaxel.
Primiano Pio Di Mauro, Salvador Borrós. Pharmaceutical Research 06/2014; 31(12).
Peptide-functionalized and high drug loaded novel nanoparticles as dual-targeting drug delivery system for modulated and controlled release of paclitaxel to brain glioma.
Primiano Pio Di Mauro, A. Cascante, P. Brugada-Vila, J.Llop, S. Borròs. Journal of Controlled Release (Pending)
Targeted proteomics in urinary extracellular vesicles indentifies biomarkers for diagnosis and prognosis of prostate cancer.
Sequeiros T. et al. 6;